HKHyuktae Kwon

Hyuktae Kwon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hyuktae Kwon has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Response: Association of Body Mass Index-Adjusted Body Cell Mass and Lean Body Mass with Metabolic Syndrome and Insulin Resistance in Middle-Aged and Older Adults: A Cross-Sectional Study (J Obes Metab Syndr 2026;35:61-71)

    by Sinyoung Cho, Joongyub Lee, Jae Moon Yun, Hyuktae Kwon

    Sinyoung Cho, Joongyub Lee, Jae Moon Yun, Hyuktae Kwon. J Obes Metab Syndr 2026;35:506-7. https://doi.org/10.7570/jomes26030

  • Open Access

    Validation of ring-type cuffless blood pressure (BP) monitoring device for detecting awake-asleep BP variations compared to ambulatory BP monitoring device

    by Seung-Mok Lee, Hyuktae Kwon, Belong Cho, Jin Ho Park, Sang-Hoon Na, Seung-Pyo Lee, Hae-Young Lee

    We evaluated the accuracy of a ring-type cuffless BP device (CART BP Pro) in detecting awake–asleep BP changes compared to conventional 24-h ambulatory BP monitoring (ABPM), following the validation protocol recommended by the European Society of Hypertension (ESH). Among 84 recruited patients, 35 were selected to satisfy ESH recommendations: 30% ( n = 11) with systolic BP (SBP) ≥ 130 mmHg and diastolic BP (DBP) ≥ 80 mmHg and 30% ( n = 11) with SBP < 120 mmHg and DBP < 70 mmHg. The remaining 40% ( n = 13) were included sequentially based on recruitment order. CART BP Pro was calibrated at least one day prior to simultaneous monitoring with ABPM. Participants simultaneously wore both devices on the non-dominant arm for 24 h. Mean SBP/DBP values and awake–asleep BP changes were compared. Awake–asleep SBP/DBP changes were 15.61 ± 8.74/11.35 ± 6.22 mmHg (ABPM) and 13.87 ± 9.04/11.44 ± 8.62 mmHg (CART BP Pro). Differences in mean awake–asleep BP changes were −1.74 ± 6.47 mmHg (SBP) and 0.08 ± 5.84 mmHg (DBP). Correlation analysis showed clinically significant correlation for both SBP and DBP changes ( r = 0.736, p < 0.01). Bland–Altman plots showed acceptable agreement with a mean difference and 95% limits of agreement of −1.74 (−14.42, 10.94) mmHg for SBP and 0.08 (−11.37, 11.53) mmHg for DBP. For four-category dipping classification, CART BP Pro showed moderate agreement with ABPM (weighted κ = 0.58). In conclusion, CART BP Pro showed a meaningful level of agreement with ABPM in detecting awake–asleep BP changes. As this addressed only the awake/asleep test of the ESH protocol, the device cannot yet replace conventional 24-h ABPM pending completion of the remaining validation tests.


  • Open Access

    Current guidelines and future directions in comprehensive obesity assessment

    by Sinyoung Cho, Hyuktae Kwon

    Obesity is a chronic systemic disease with multifactorial causes that poses a substantial health and economic burden worldwide. In Korea, obesity is a significant public health concern owing to the increasing prevalence of obesity-related comorbidities and mortality. Obesity is defined as excess adiposity that poses health risks. Adiposity can be assessed using direct and indirect methods, among which body mass index (BMI) is the most widely used anthropometric measurement in epidemiological studies and clinical practice. However, limitations of BMI-centric obesity assessments have been noted in previous studies. Simple adiposity measures cannot capture obesity-related medical conditions, daily functional status, or mental health. Therefore, medical associations worldwide have increasingly emphasized the need for comprehensive obesity assessments, including the 2020 Canadian Adult Obesity Clinical Practice Guidelines, American Association of Clinical Endocrinologists/American College of Endocrinology 2023 Guidelines, 2024 European Association for the Study of Obesity diagnostic framework, and 2025 Lancet Commission’s Clinical Obesity Diagnostic Criteria. Recent perspectives have emphasized multidimensional approaches to obesity assessment to capture individuals’ overall health status. This review aims to evaluate the limitations of BMI-centric obesity diagnosis, summarize emerging recommendations from recent international guidelines, and highlight potential alternative approaches for improving the assessment of obesity and related health outcomes.


  • Open Access

    Association of Body Mass Index-Adjusted Body Cell Mass and Lean Body Mass with Metabolic Syndrome and Insulin Resistance in Middle-Aged and Older Adults: A Cross-Sectional Study

    by Sinyoung Cho, Joongyub Lee, Jae Moon Yun, Hyuktae Kwon

    Sinyoung Cho, Joongyub Lee, Jae Moon Yun, Hyuktae Kwon. J Obes Metab Syndr -0001;0:0-. https://doi.org/10.7570/jomes25022


  • Open Access

    2024 Clinical Practice Guidelines for the Diagnosis and Pharmacologic Treatment of Overweight and Obesity by the Korean Society for the Study of Obesity

    by Jae Hyun Bae, Ji-Hee Haam, Eonju Jeon, Seo Young Kang, SuJin Song, Cheol-Young Park, Hyuktae Kwon, the Clinical Guidelines Committee of the Korean Society for Study of Obesity

    Jae Hyun Bae, Ji-Hee Haam, Eonju Jeon, Seo Young Kang, SuJin Song, Cheol-Young Park, Hyuktae Kwon, on Behalf of the Clinical Guidelines Committee of the Korean Society for Study of Obesity. J Obes Metab Syndr -0001;0:0-. https://doi.org/10.7570/jomes25042


  • Open Access

    Higher Physical Activity is Associated with Reduced Lower Urinary Tract Symptoms in Korean Men

    by Seo Eun Hwang, Jae Moon Yun, Su Hwan Cho, Kyungha Min, Ji Young Kim, Hyuktae Kwon, Jin Ho Park

    Hwang SE, et al. World J Mens Health. 2025 Jan;43(1):166-173. https://doi.org/10.5534/wjmh.230303


  • Open Access

    Association between Chronic Atrophic Gastritis and Bone Mineral Density among Women Older than 40 Years of Age in Korea

    by Seulki Lee, Jae Moon Yun, Jin-Ho Park, Hyuktae Kwon

    Background: Chronic atrophic gastritis causes hypochlorhydria, hypergastrinemia, and malabsorption of nutrients, leading to lower bone mineral density. The few studies that investigated the association between chronic atrophic gastritis and bone mineral density have reported inconsistent findings. As such, the present study assessed the association between chronic atrophic gastritis and bone mineral density among a large sample of women >40 years of age in Korea.Methods: Data from 8,748 women >40 years of age who underwent esophagogastroduodenoscopy and bone densitometry were analyzed. Chronic atrophic gastritis was diagnosed using esophagogastroduodenoscopy. Bone mineral density of the lumbar vertebrae (L), femur neck, and femur total, measured using dual-energy X-ray absorptiometry, were the primary outcome variables. Low bone mineral density, which could be diagnosed as osteoporosis or osteopenia, was defined and analyzed as a secondary outcome. Linear regression was used to calculate adjusted mean values of bone mineral density. The association between low bone mineral density and chronic atrophic gastritis was analyzed using multiple logistic regression.Results: The adjusted mean bone mineral density for L1–L4 was 1.063±0.003, femur neck (0.826±0.002), and femur total (0.890±0.002) were significantly lower in patients with chronic atrophic gastritis than others (1.073±0.002, 0.836±0.001, 0.898±0.002, respectively; all P<0.01). Women with chronic atrophic gastritis exhibited an increased likelihood for osteopenia or osteoporosis, even after adjusting for age and other confounding factors (odds ratio, 1.25; 95% confidence interval, 1.13–1.40; P<0.01). However, subgroup analysis revealed statistical significance only in postmenopausal women (odds ratio, 1.27; P<0.001).Conclusion: Chronic atrophic gastritis was associated with lower bone mineral density and a higher risk for osteopenia or osteoporosis among postmenopausal women.


  • Open Access

    Feasibility and Effectiveness of a Ring-Type Blood Pressure Measurement Device Compared With 24-Hour Ambulatory Blood Pressure Monitoring Device

    by Huijin Lee, Sungjoon Park, Hyuktae Kwon, Belong Cho, Jin Ho Park, Hae-Young Lee

    Lee H, et al. Korean Circ J. 2024 Feb;54(2):93-104. https://doi.org/10.4070/kcj.2023.0303


  • Open Access

    Association between serum uric acid level and bone mineral density in men more than 50 years of age

    by Sujin Kim, Seulki Lee, Hyuktae Kwon

    Background: The results of previous studies on the association between serum uric acid levels and bone mineral density and the risk of osteoporosis are controversial. Fat free mass (FFM) is more strongly associated with bone mineral density (BMD) than it is with body fat mass (BFM). Skeletal muscle mass is assumed to contribute indirectly to the relationship between serum uric acid levels and BMD. Therefore, we aimed to evaluate the association between serum uric acid levels and BMD and abnormal BMD (at least osteopenia) by considering body composition in men aged ≥ 50 years.Methods: This was a retrospective observational cross-sectional study. We used data obtained from 2,991 men aged ≥50 years who completed questionnaires, anthropometric surveys, laboratory tests, and bone mineral density scans. A subgroup analysis of 1,135 men who additionally underwent body composition data analysis using Inbody® was performed. Multiple linear regression analysis was used to explore the relationship between serum uric acid levels and BMD at three sites (L1-L4, Femur neck, Femur total). In addition, multiple logistic regression analysis was performed to determine the association of serum uric acid levels with abnormal BMD (at least osteopenia).Results: Positive correlations between serum uric acid levels and BMD at the three sites (L1-L4, Femur neck, Femur total) were observed in unadjusted and fully adjusted models except the BMD of the femoral neck (P-value=0.054).Furthermore, FFM and skeletal muscle mass index (SMI) showed positive association with serum uric acid level and BMD at three sites, with statistical significance. An increase in serum uric acid level was associated with a lower risk of abnormal BMD after adjusting for confounders including FFM and SMI.Conclusion: Serum uric acid level was positively associated with BMD at three sites and had a protective effect against abnormal BMD after adjusting for multiple confounders, including FFM and SMI, in men aged ≥ 50 years.


  • Open Access

    Effect of anti-obesity agent HSG4112 on overweight and obese patients following 12 weeks of oral treatment: a study protocol for a randomised, double-blind, placebo-controlled, parallel-group, phase 2a clinical trial

    by Kyungha Min, Bumjo Oh, Hye Yeon Koo, Yang-Hyun Kim, Ji-Won Lee, Sangsub Lee, Youngah Kim, Hyuktae Kwon

    Background: Glaceum Inc. has proposed HSG4112, a structural analogue of glabridin, as a novel anti-obesity compound. Animal studies and phase I human trials have shown that HSG4112 improves energy consumption, normalises weight, and is safe and drug-resistant. Based on these results, the company plans to conduct a phase 2a clinical trial to determine the safety and efficacy of HSG4112 in overweight and obese patients. Methods: A 16-week randomised, double-blind, placebo-controlled, parallel-group trial will be conducted at five large hospitals in South Korea to assess the safety and efficacy of HSG4112 in overweight and obese patients. Participants who meet the inclusion/exclusion criteria will be assigned a subject number and randomly assigned to one of the four treatment groups (one group receiving a placebo) in a 1:1:1:1 ratio. The study’s primary outcome will be to monitor the change in body weight (kg) from baseline to the end of treatment while monitoring safety and tolerability. Discussion: This trial will evaluate the efficacy and safety of HSG4112 in overweight and obese adults. Upon proving the safety and effectiveness of the newly developed mechanism, it might significantly improve the perception of the product among medical personnel and obese patients. Furthermore, it may aid in managing chronic conditions that require long-term treatment.Trial registration:ClinicalTrials.gov, identifier [NCT05197556].